Menopausal Estrogen Therapy and Risk for Benign Proliferative Breast Disease

WHI analysis showed that ET was associated with doubling of risk for BPBD.

Benign proliferative breast disease (BPBD) is a relatively common condition diagnosed on breast biopsy; however, evidence about the role of estrogen therapy (ET) in the development of BPBD has been inconsistent. Using data from the Women’s Health Initiative (WHI) trial, investigators evaluated risk for incident BPBD during 6.9 years of follow-up in post-hysterectomy women randomized to conjugated equine estrogen (0.625 mg per day) versus placebo. Participants underwent baseline and annual clinical breast examinations and mammographies.

Overall, 232 new cases of BPBD were diagnosed among 10,739 participants; approximately two thirds of cases were among women taking ET. The risk for being diagnosed with BPBD without atypia was more than twice …

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Menopausal Estrogen Therapy and Risk for Benign Proliferative Breast Disease

Topics

Reviewing Author